: This biotechnology firm was a standout, posting a 426% return in 2017. Its growth was driven by positive clinical trial results for its cholesterol-reducing drug candidate.
: Expectations of tax cuts and increased infrastructure support under the new U.S. administration provided a tailwind for industrial and homebuilding stocks like Boeing (BA) and D.R. Horton (DHI) . high risk stocks to buy 2017
: The maker of Invisalign benefited from a near-monopoly on invisible braces, seeing a 131% increase as it expanded its training to thousands of dentists globally. : This biotechnology firm was a standout, posting
: Nine of the top ten performing stocks of the year were in the biotech sector. Companies like Vertex Pharmaceuticals (VRTX) (up 97%) and Dynavax Technologies (DVAX) (up 373%) succeeded based on FDA approvals and breakthrough trial data. : Nine of the top ten performing stocks
The following stocks represented some of the most successful speculative plays for the year: